Compass Pathways reports Q2 2026 results, cites Phase 3 data as NDA filing nears
Compass says its rolling NDA submission for COMP360 in treatment-resistant depression is on track for completion in the fourth quarter, with a possible launch in the first half of 2027.
SEC filing